Trial Search Results

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL).

This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Stanford Investigator(s):


  • Drug: Entospletinib
  • Drug: Vincristine
  • Drug: Dexamethasone
  • Drug: CNS Prophylaxis


Phase 1/Phase 2


Key Inclusion Criteria:

   - Adults with ALL in need of treatment

Key Exclusion Criteria:

   - Diagnosis of Burkitt's Leukemia, or lymphoid blast crisis of chronic myelogenous
   leukemia (CML)

   - History of myelodysplastic syndrome or solid organ transplantation

   - Prior allogeneic bone marrow progenitor cell transplant within 100 days or on active
   immunosuppression for graft versus host disease (GVHD) treatment or prophylaxis within
   28 days prior to enrollment

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting